Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785892 | 0.84 | FKBP1A (0.37) | MEN1KMT2ACCR2 | |
| SCHEMBL785974 | 0.80 | FKBP1A (0.35) | MEN1KMT2A | |
| SCHEMBL26650279 | 0.78 | KMT2A (0.34) | MEN1KMT2A | |
| SCHEMBL12395034 | 0.77 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL8979439 | 0.77 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL3346305 | 0.77 | NAAA (0.53) | NAAAMEN1KMT2A | |
| SCHEMBL15697297 | 0.77 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL8979423 | 0.76 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL6901495 | 0.76 | NAAA (0.59) | NAAA | |
| SCHEMBL26338839 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122089-A1 | Analogs of andandamide and arvanil have been found to act at receptors; are useful in pain management, used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications | VIRGINIA COMMONWEALTH UNIVERSITY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122089-A1 | Analogs of andandamide and arvanil have been found to act at receptors; are useful in pain management, used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications | CNR1, AVPR1A, OPRL1 | NAAA 133/4885MEN1 4164/4885KMT2A 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.